A detailed history of Northern Trust Corp transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 308,850 shares of ABOS stock, worth $731,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares
308,850
Previous 70,088 340.66%
Holding current value
$731,974
Previous $169,000 352.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.22 - $3.54 $530,051 - $845,217
238,762 Added 340.66%
308,850 $765,000
Q2 2024

Aug 14, 2024

BUY
$2.14 - $4.01 $28,494 - $53,393
13,315 Added 23.45%
70,088 $169,000
Q1 2024

May 14, 2024

BUY
$2.97 - $4.64 $282 - $440
95 Added 0.17%
56,773 $229,000
Q4 2023

Feb 13, 2024

BUY
$1.86 - $4.48 $907 - $2,186
488 Added 0.87%
56,678 $217,000
Q3 2023

Nov 13, 2023

BUY
$4.15 - $9.72 $99,998 - $234,213
24,096 Added 75.08%
56,190 $233,000
Q2 2023

Aug 11, 2023

SELL
$3.59 - $6.59 $229 - $421
-64 Reduced 0.2%
32,094 $154,000
Q1 2023

May 15, 2023

SELL
$3.75 - $6.65 $8,347 - $14,802
-2,226 Reduced 6.47%
32,158 $130,000
Q4 2022

Feb 13, 2023

BUY
$4.81 - $10.17 $41,568 - $87,889
8,642 Added 33.57%
34,384 $185,000
Q3 2022

Nov 14, 2022

BUY
$4.44 - $10.48 $18,630 - $43,974
4,196 Added 19.47%
25,742 $259,000
Q2 2022

Aug 12, 2022

SELL
$3.08 - $4.88 $599,435 - $949,755
-194,622 Reduced 90.03%
21,546 $101,000
Q1 2022

May 13, 2022

BUY
$3.91 - $6.73 $473,829 - $815,568
121,184 Added 127.58%
216,168 $845,000
Q4 2021

Feb 08, 2022

BUY
$6.54 - $15.31 $49,592 - $116,095
7,583 Added 8.68%
94,984 $642,000
Q3 2021

Nov 15, 2021

BUY
$14.5 - $20.28 $1.27 Million - $1.77 Million
87,401 New
87,401 $1.3 Million

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $96M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.